Guardant Health Inc

GH is in a robust Stage 2 advance with a parabolic acceleration above rising EMAs, anchoring bullish medium- and long-term biases. However, extreme overbought conditions and an exhaustion candle near the peak suggest near-term timing is unfavorable. Execution should be deferred until a pullback into the rising EMA 9/21 support zone or prior consolidation range confirms renewed buying interest.

• ↑Q2 2026 revenue reached $335M, up 44% YoY driven by Guardant360 and Shield tests.
• ↑Oncology test volumes climbed 63% YoY to ~104K tests, reflecting strong market adoption.
• ↓Patent infringement verdict carries $245.2M damages, straining cash flows and management focus.